loteprednol

(redirected from Lotemax)

loteprednol

 [lo″tĕ-pred´nol]
a corticosteroid applied topically to the conjunctiva in the treatment of seasonal allergic conjunctivitis, postoperative inflammation, and ocular inflammatory disorders.

loteprednol

/lo·te·pred·nol/ (lo″tĕ-pred´nol) a corticosteroid applied topically to the conjunctiva in the treatment of seasonal allergic conjunctivitis, postoperative inflammation, and ocular inflammatory disorders.

loteprednol

[lo′tĕpred′nol]
a corticosteroid applied topically to the conjunctiva in the treatment of seasonal allergic conjunctivitis, postoperative inflammation, and ocular inflammatory disorders.
References in periodicals archive ?
Bausch + Lomb has a broad portfolio of eye health products, including well-known prescription and OTC brands Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, renu and Boston; and surgical brands enVista, Storz, Stellaris and VICTUS.
Under the terms of the agreement, both the Pfizer and Bausch & Lomb sales forces will promote Xalatan, Alrex, Lotemax, Zylet and besifloxacin (subject to FDA approval).
Bausch + Lomb is a leading global eye health company that has a broad portfolio of eye health products, including well-known prescription and OTC brands Besivance, Lotemax, Ocuvite and PreserVision; vision care brands Biotrue ONEday, PureVision, renu and Boston; and surgical brands enVista, Storz, Stellaris and VICTUS.
As with other ophthalmic corticosteroids, Lotemax is contraindicated in most viral diseases of the cornea and conjunctiva and in mycobacterial and fungal diseases of the eye.
Approved by the FDA in late September 2012 and launching in the next few months is LOTEMAX (loteprednol etabonate ophthalmic gel) 0.
Ocuvite, ReNu MultiPlus, Boston Simplus, PureVision, Alaway, Lotemax, Zylet and Alrex are trademarks of Bausch & Lomb Incorporated.
ISTA's four prescription products, BROMDAY(TM), BEPREVE, ISTALOL, and VITRASE, will complement Bausch + Lomb's existing prescription ophthalmology products, including Lotemax and Besivance, and branded OTC eye vitamins PreserVision and Ocuvite.
Susan also worked for B+L as the head of pharmaceutical sales and commercial operations where she launched their first branded pharmaceutical products including Lotemax and Alrex.
It is gratifying that our collaborative development of our loteprednol etabonate business with Bausch & Lomb that produced two earlier successful proprietary anti-inflammatory products, Lotemax and Alrex, has culminated in the commercialization of Zylet.
Under the terms of the transaction, Pharmos received from Bausch & Lomb approximately $25 million in cash for the sale of Lotemax and Alrex, and will receive an amount estimated at approximately $14 million for LE-T, a third product in advanced clinical development, upon its approval by the FDA, the exact amount of which will be determined based on the actual approval date.
7 million from the proceeds of the sale of Lotemax and Alrex in return for his consent to Pharmos' assignment of its rights under the license agreement to Bausch & Lomb, and will also pay the patent owner a portion of the LE-T sale proceeds and a portion of its milestone payment.